Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004554 · ClinicalTrials.gov registry record · Phase 4
Sertraline for Alcohol Dependence and Depression
A Phase 4 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 171
- Enrollment target
NCT00004554: Completed Phase 4 study, sponsored by University of Pennsylvania.
NCT00004554 is a Phase 4 study that has completed, run by University of Pennsylvania. The registered enrollment target is 171 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004554, a Phase 4 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 171 participants
- Enrollment target
Study Summary
This study will examine depressed alcoholic outpatients to assess whether combining naltrexone (Revia) and sertraline (Zoloft) will result in greater reductions in both drinking and depression over either medication alone or placebo. A secondary aim is to determine whether certain patient features will predict response to sertraline, naltrexone or the combination of the two drugs. Subjects will be randomized into treatment groups for 14 weeks. The followup phase includes two visits at 6 and 9 months after treatment.
Interventions
- DRUG Placebo
- DRUG naltrexone (Revia)
- DRUG sertraline (Zoloft)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2000-01 |
| Est. Completion | 2006-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004554
The ClinicalTrials.gov registry entry for NCT00004554 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 171 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00004554 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004554 about?
NCT00004554 is a clinical study titled "Sertraline for Alcohol Dependence and Depression". This study will examine depressed alcoholic outpatients to assess whether combining naltrexone (Revia) and sertraline (Zoloft) will result in greater reductions in both drinking and depression over either medication alone or placebo. A secondary aim is to determine whether certain patient features w...
What is the current status of trial NCT00004554?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 171 participants. The study started on 2000-01. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00004554?
The interventions under investigation include: Placebo (DRUG), naltrexone (Revia) (DRUG), sertraline (Zoloft) (DRUG).
Who is sponsoring clinical trial NCT00004554?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.